Tamarisk Technologies Group Announces New Addition to Science Team

LAS VEGAS, Sept. 5, 2014 /PRNewswire/ -- Tamarisk Technologies Group, LLC, a technology development company engaged in the development of innovative drug delivery technology, announced last week that it has added Dr. Mel Affrime to the Tamarisk team as Director of Scientific Affairs. 

"We are excited to have Mel on the Tamarisk team," says Dean Crowell, Executive Director of Tamarisk Technologies Group.  "His experience and expertise in global clinical research and development will be invaluable as we enter the pre-clinical phase and subsequent clinical trials for our oral drug delivery system. Mel will play a vital role in preparing for our upcoming lab work and structuring our test data to engage the market."

"I'm excited to be a part of the Tamarisk Team!" says Dr. Affrime. "I'm looking forward to taking our SSNE system to the industry. With our novel technology, we are poised to revolutionize the drug delivery market."

Tamarisk Technologies was founded in 2008 with a mandate to release strategic technological solutions for various industries based upon real-world studies of Biomimicry. In early 2012, Tamarisk unveiled a successful development of the first viable oral insulin using its novel Serum-Specific Nano-Encapsulation (SSNe) transport technology, as well as pegylated peptides, vitamins, minerals and other pharmaceuticals previously available only intravenously.

"Our mission at Tamarisk is to apply the natural macroscopic and microscopic symbiosis found in nature to the development of biotechnologies," says A.T. Snoots, Tamarisk's Director of Operations. "Our #NoMoreNeedles campaign promoting our SSNe technology for the development of orally administered insulin is just one example of how Tamarisk's technology will benefit society."

About Tamarisk Technologies Group LLC

Tamarisk Technologies Group is a scientific research and development company that has recently undergone significant organizational changes. At Tamarisk, we are engaged in the invention of all-natural therapeutic agents, drug delivery transport vehicles, "green chemistry" for production of innovative products and manufacturing processes and the provision of high-value technologies that exceed the confines of traditional scientific philosophy.

Mel Affirme Bio

Dr. Affirme completed his PharmD training at PCP&S in Philadelphia and Clinical Pharmacology Fellowship with Marcus Reidenberg, M.D. at Temple University College of Medicine. He then co-founded the Clinical Pharmacology research unit at Hahnemann Hospital, Philadelphia, Pennsylvania with David Lowenthal, M.D., Ph.D. in 1976. He remained on the faculty at Hahnemann until 1982 when he joined Hoechst-Roussel Pharmaceuticals as Associate Director, Clinical Pharmacology. In 1985 he joined the Schering-Plough Research Institute as Director, Clinical Pharmacology. During his 16 years at Schering, he managed the early development programs for the entire Schering pipeline and was named VP, Clinical Pharmacology, Clinical Research in 1996. Mel left Schering in 2001 to Join Novartis Pharmaceuticals as Global Head of Profiling Clinical Pharmacology. He was at Novartis until 2006 when he joined ICON Development Solutions as Sr. VP and Chief Scientific Officer. He remained at ICON until 2011 where he managed the medical staff at ICON's 3 CPUs, the Population PK software business and the R&D department. Mel is now the Sr. VP, Translational Medicine at WCCT Global.

Media Contact: A. T. Snoots, (for Tamarisk Technologies Group, LLC), 702.516.6451, Email

SOURCE Tamarisk Technologies Group